ライフサイエンスコーパス: atazanavir

1 r a boosted protease inhibitor (darunavir or atazanavir).

2 citabine plus efavirenz or ritonavir-boosted atazanavir.

3 ortant in decreasing the binding affinity of atazanavir.

4 aining the antiretroviral protease inhibitor atazanavir.

5 eived at least one dose of ritonavir-boosted atazanavir.

6 rodrugs of the HIV-1 protease inhibitor (PI) atazanavir (1) were prepared and evaluated to address so

7 ugs of the marketed HIV-1 protease inhibitor atazanavir (1), designed to enhance the systemic drug de

8 CI 1.10-1.19], p<0.0001), ritonavir-boosted atazanavir (1.20 [1.13-1.26], p<0.0001), and ritonavir-b

9 diate/high-level resistance to lopinavir and atazanavir; 17% had intermediate-level resistance (none

10 CI, 0%-3.8%) and highest for ZDV+3TC+boosted atazanavir (21.2%; 95% CI, 13.5%-30.0%).

11 r-boosted darunavir (232), ritonavir-boosted atazanavir (231), and ritonavir-boosted lopinavir (227).

12 r group) or continued their current regimen (atazanavir 300 mg and ritonavir 100 mg once daily or lop

13 , or 1200 mg once daily or ritonavir-boosted atazanavir (300 mg of atazanavir and 100 mg of ritonavir

14 Morning administration of atazanavir (300 mg once daily) and darunavir regimens ex

15 tonavir exposures, evening administration of atazanavir (300 mg) plus ritonavir (100 mg) or lopinavir

16 cell count of 225/mm(3) began treatment with atazanavir (300 mg), ritonavir (100 mg), emtricitabine (

17 Atazanavir, 300 mg/d, with ritonavir, 100 mg/d; raltegra

18 In these two complexes, atazanavir adopts distinct bound conformations in respon

19 Maintenance therapy with ritonavir-boosted atazanavir alone is a possible option because of low pil

20 superior to ritonavir-boosted lopinavir and atazanavir analyzed in combination (adjusted difference,

21 superior to ritonavir-boosted lopinavir and atazanavir analyzed in combination, and that ritonavir-b

22 y or ritonavir-boosted atazanavir (300 mg of atazanavir and 100 mg of ritonavir once daily), each wit

23 = .89) (median, 69 ng/mL and 74 ng/mL in the atazanavir and darunavir arms, respectively) and were no

24 D regimen can be coadministered with morning atazanavir and darunavir regimens.

25 ynthesis of HIV protease inhibitors, such as atazanavir and darunavir.

26 ty and replication capacity was observed for atazanavir and lopinavir but not darunavir.

27 Ten-fold variation in susceptibility to PIs atazanavir and lopinavir was observed across 20 viruses,

28 Both atazanavir and saquinavir exhibited a remarkable synergi

29 identified that two HIV protease inhibitors, atazanavir and saquinavir, in combination with posaconaz

30 and to other protease inhibitors, including atazanavir and two experimental compounds.

31 tegravir), 2 protease inhibitors (darunavir, atazanavir), and 2 nonnucleoside reverse transcriptase i

32 tance to lopinavir, 58% showed resistance to atazanavir, and >60% showed resistance to saquinavir, in

33 f tenofovir disoproxil fumarate, saquinavir, atazanavir, and an integrase inhibitor starting at 12 da

34 se (eg, efavirenz, lopinavir plus ritonavir, atazanavir, and darunavir).

35 bation for efavirenz, nevirapine, lopinavir, atazanavir, and elvitegravir.

36 darunavir was superior to ritonavir-boosted atazanavir, and raltegravir was superior to both proteas

37 ls were tenofovir, emtricitabine, efavirenz, atazanavir, and raltegravir.

38 Tenofovir, ritonavir-boosted atazanavir, and ritonavir-boosted lopinavir use were ind

39 ibitors (ritonavir, lopinavir/ritonavir 4:1, atazanavir, atazanavir/ritonavir 4:1) or vehicle.

40 Of specific drugs investigated, atazanavir, atazanavir/ritonavir, fosamprenavir, indinav

41 004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, o

42 or 6 days and then received PI/r as follows: atazanavir (ATV) 300 mg once daily, lopinavir (LPV) 400

43 sus ritonavir (RTV) as a pharmacoenhancer of atazanavir (ATV) in combination with emtricitabine (FTC)

44 the role of RTV in the bidirectional TVR and atazanavir (ATV) interactions.

45 Atazanavir (ATV) is a once-daily human immunodeficiency

46 substitution is observed in patients failing atazanavir (ATV) therapy.

47 fumarate/emtricitabine and ritonavir-boosted atazanavir (ATV) underwent serial paired cervicovaginal

48 Ritonavir (RTV) and atazanavir (ATV) were co-formulated with polyvinylpyrrol

49 nocrystals containing the protease inhibitor atazanavir (ATV) were prepared by high-pressure homogeni

50 ed 40 mg or 80 mg GSK3532795 once daily with atazanavir (ATV) with or without (+/-) ritonavir (RTV) o

51 y virus (HIV)-infected patients receiving an atazanavir (ATV)-based antiretroviral regimen developed

52 o were exposed to darunavir (DRV) but not to atazanavir (ATV).

53 -boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-

54 between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r

55 d maintenance therapy with ritonavir-boosted atazanavir (ATV/RTV) alone is attractive because of nucl

56 , emtricitabine [FTC], and ritonavir-boosted atazanavir [ATV]) with suppressed plasma virus loads, bl

57 PV plus TDF (n = 301); and ritonavir-boosted atazanavir (ATZ/r) plus TDF (n = 250).

58 T (n = 25), efavirenz-based ART (n = 25), or atazanavir-based ART (n = 24).

59 ded protease inhibitor treatments for HIV is Atazanavir boosted with Ritonavir (ATV/r).

60 Structural analysis of atazanavir bound to a pretherapy B protease showed that

61 PIs (ritonavir, lopinavir, and atazanavir) but not nucleoside reverse transcriptase inh

62 Here, we show that the PIs nelfinavir and atazanavir cause cell death in various malignant glioma

63 r risk of virologic failure at 12 months for atazanavir compared with lopinavir regimens.

64 Plasma atazanavir concentrations at failure were low or below d

65 ary outcomes, efavirenz or ritonavir-boosted atazanavir concentrations were assessed by 8-h intensive

66 sures included HIV-1 drug resistance, plasma atazanavir concentrations, adverse events, CD4 cell coun

67 pants remained protected from subtherapeutic atazanavir concentrations.

68 Compared with PK1, atazanavir Ctau, and AUC were significantly reduced at P

69 The HIV-1 PIs assessed included atazanavir, darunavir, and lopinavir (administered with

70 The AUC(0-8 h) of efavirenz or atazanavir did not differ between the groups.

71 Atazanavir did not impact ubiquitin or proteasomal gene

72 fovir dramatically increased clearance while atazanavir did not.

73 been associated with hyperbilirubinemia and atazanavir discontinuation.

74 In a comparison with ritonavir-boosted atazanavir, efficacy and safety of BMS-663068 up to the

75 dine-zidovudine plus efavirenz, n = 289), B (atazanavir, emtricitabine, and didanosine-EC, n = 293),

76 copies per mL or more and susceptibility to atazanavir, emtricitabine, and tenofovir.

77 With first-trimester atazanavir exposure, risks were highest for skin (aOR, 5

78 se was observed in successive years and with atazanavir exposure.

79 either the dolutegravir group (n=250) or the atazanavir group (n=249); two participants from each gro

80 of the 51 patients in the ritonavir-boosted atazanavir group discontinued because of adverse events.

81 group compared with 176 (71%) of 247 in the atazanavir group had HIV-1 RNA viral loads of less than

82 One participant in the atazanavir group had nucleoside reverse transcriptase in

83 ticipants in the dolutegravir group than the atazanavir group reported drug-related adverse events (8

84 dose relation and for the ritonavir-boosted atazanavir group these were mostly gastrointestinal or h

85 dolutegravir group vs 49 [20%] of 247 in the atazanavir group) and headache (28 [11%] vs 32 [13%]).

86 roxil fumarate and emtricitabine once a day (atazanavir group).

87 up, 25 in the efavirenz group, and 24 in the atazanavir group.

88 of the 51 patients in the ritonavir-boosted atazanavir group.

89 75%) of 51 patients in the ritonavir-boosted atazanavir group.

90 I, -.13 to 16.43) cells/microL higher in the atazanavir group.

91 27%) of 51 patients in the ritonavir-boosted atazanavir group.

92 ts were similar between the dolutegravir and atazanavir groups; the most common were nausea (46 [19%]

93 st, participants receiving ritonavir-boosted atazanavir had 71% higher etonogestrel (1.71, 1.37-2.14;

94 otease inhibitors (ritonavir, indinavir, and atazanavir) induce endoplasmic reticulum stress and acti

95 f its nearly symmetrical chemical structure, atazanavir is able to make several analogous contacts wi

96 Atazanavir is contraindicated with glecaprevir/pibrentas

97 ble of propagating at high-concentrations of atazanavir, lopinavir, and amprenavir (APV).

98 wed low-level cross-resistance to darunavir, atazanavir, lopinavir, and saquinavir, but not other PIs

99 00 mg once daily group) or ritonavir-boosted atazanavir (n=51).

100 As previously reported, atazanavir offers improved inhibitory profiles against s

101 nz), a ritonavir-boosted protease inhibitor (atazanavir or darunavir), or an integrase strand transfe

102 ubjects were randomized to ritonavir-boosted atazanavir or darunavir, or raltegravir-based cART.

103 ble increases in lipids observed with either atazanavir or darunavir.

104 o harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low

105 imens consisting of either ritonavir-boosted atazanavir or ritonavir-boosted lopinavir and a nucleosi

106 dolutegravir or ritonavir-boosted darunavir, atazanavir, or lopinavir as the anchor drug.

107 fovir disoproxil fumarate, ritonavir-boosted atazanavir, or ritonavir-boosted lopinavir therapy.

108 a HIV-1 RNA suppressed while taking a stable atazanavir- or raltegravir-inclusive antiretroviral regi

109 hree-tablet combination of ritonavir-boosted atazanavir plus coformulated tenofovir disoproxil fumara

110 nz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC plus emtricitabine (ATV+DD

111 pants with virologic failure, those assigned atazanavir plus ritonavir (ATV/r) did not have significa

112 We aimed to evaluate treatment responses to atazanavir plus ritonavir (ATV/r) or efavirenz (EFV) in

113 -emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus ritonavir (ATV/r), on bone mineral densi

114 e patients were randomly assigned to receive atazanavir plus ritonavir and 465 were assigned to recei

115 icacy was similar in the group that received atazanavir plus ritonavir and and the group that receive

116 Atazanavir plus ritonavir and efavirenz have similar ant

117 The third drugs, atazanavir plus ritonavir and efavirenz, were open-label

118 However, evening atazanavir plus ritonavir and lopinavir/ritonavir regime

119 Open-label atazanavir plus ritonavir or efavirenz, each given with

120 < 0.001) events was longer in persons given atazanavir plus ritonavir than in those given efavirenz

121 The atazanavir/posaconazole and saquinavir/posaconazole comb

122 an association between *28/*28 and increased atazanavir/r discontinuation among Hispanic participants

123 The positive predictive value of 28*/28* for atazanavir/r discontinuation among Hispanic participants

124 A total of 646 atazanavir/r recipients were evaluable for UGT1A1.

125 ed patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine

126 detection for regimens including darunavir, atazanavir, raltegravir or dolutegravir.

127 ility failure, defined as discontinuation of atazanavir, raltegravir, or darunavir for toxicity.

128 ection for regimens that included darunavir, atazanavir, raltegravir, or dolutegravir.

129 or deaths), and 4301 individuals started an atazanavir regimen (83 deaths, 157 AIDS-defining illness

130 utegravir combined regimen compared with the atazanavir regimen support the use of dolutegravir for H

131 as superior to that of the ritonavir-boosted atazanavir regimen.

132 from the time they started a lopinavir or an atazanavir regimen.

133 for tolerability, whereas ritonavir-boosted atazanavir resulted in a 12.7% and 9.2% higher incidence

134 avir, amprenavir, saquinavir, lopinavir, and atazanavir revealed that the natural polymorphisms found

135 (nanoART) through modifications of existing atazanavir, ritonavir, and efavirenz suspensions in orde

136 nofovir-emtricitabine plus ritonavir-boosted atazanavir, ritonavir-boosted darunavir, or raltegravir.

137 fovir disoproxil fumarate, ritonavir-boosted atazanavir, ritonavir-boosted lopinavir, other ritonavir

138 ed to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r

139 ricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir-ritonavir (ATV/r).

140 est that simplified maintenance therapy with atazanavir-ritonavir alone may be efficacious for mainta

141 and 2 discontinued before simplification to atazanavir-ritonavir alone.

142 Atazanavir-ritonavir and raltegravir were associated wit

143 Participants switched PIs to atazanavir-ritonavir at entry and discontinued nucleosid

144 ived dolutegravir, 464 in those who received atazanavir-ritonavir, 185 in those who received darunavi

145 ir; corresponding percentages were 84.0% for atazanavir-ritonavir, 89.2% for raltegravir, and 89.8% f

146 tial ART in pregnancy included dolutegravir, atazanavir-ritonavir, darunavir-ritonavir, oral rilpivir

147 ing efavirenz-based ART (n=25), or receiving atazanavir-ritonavir-based ART (n=24).

148 type 1 (HIV-1)-infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with t

149 ricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in human immunodeficiency v

150 proxil fumarate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r

151 proxil fumarate-emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r

152 conducted to determine if efavirenz (EFV) or atazanavir/ritonavir (ATV/r)-based combination antiretro

153 When combined with atazanavir/ritonavir (n = 32), TAF AUClast increased to

154 RT-naive adults with HIV initiating ART with atazanavir/ritonavir + tenofovir/emtricitabine to a sing

155 IV-infected adults were randomly assigned to atazanavir/ritonavir 300/100 mg or darunavir/ritonavir 8

156 onavir, lopinavir/ritonavir 4:1, atazanavir, atazanavir/ritonavir 4:1) or vehicle.

157 Seven patients discontinued atazanavir/ritonavir and 5 discontinued darunavir/ritona

158 At 96 weeks, 56 (62%) atazanavir/ritonavir and 62 (71%) darunavir/ritonavir pa

159 nce interval [CI], -.6 to 21.6) and 71 (79%) atazanavir/ritonavir and 75 (85%) darunavir/ritonavir pa

160 We found no major differences between atazanavir/ritonavir and darunavir/ritonavir in efficacy

161 .9 to 55.0; P = .0362) increased more in the atazanavir/ritonavir arm than in darunavir/ritonavir arm

162 Body fat changes in the atazanavir/ritonavir arm were associated with higher ins

163 s a greater increase in triglycerides in the atazanavir/ritonavir arm.

164 We investigated whether dose escalation of atazanavir/ritonavir could safely overcome the DDI with

165 Twice daily atazanavir/ritonavir during rifampicin co-administration

166 However, atazanavir/ritonavir led to higher triglycerides and mor

167 ne transaminase occurred in combination with atazanavir/ritonavir only.

168 of people living with HIV (PLHIV) receiving Atazanavir/Ritonavir treatment at the Iranian Research C

169 Also, fat gains with atazanavir/ritonavir were associated with insulin resist

170 al drugs (efavirenz, lopinavir/ritonavir, or atazanavir/ritonavir).

171 gravir/lamivudine, raltegravir, rilpivirine, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/rit

172 se inhibitor combination, plus dolutegravir, atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/

173 fovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravi

174 fovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravi

175 receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravi

176 Of specific drugs investigated, atazanavir, atazanavir/ritonavir, fosamprenavir, indinavir, indinavi

177 % CI, 1.45-2.40), per 5 years of exposure to atazanavir/ritonavir, lopinavir/ritonavir, and tenofovir

178 uals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted

179 isk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibi

180 e with human immunodeficiency virus (HIV) on atazanavir/ritonavir-based antiretroviral therapy (ART)

181 ho were switched from lopinavir/ritonavir to atazanavir/ritonavir.

182 The target minimum concentration was atazanavir's protein-adjusted IC90 (PA-IC90), 0.014 mg/L

183 bitors, higher odds of CAs were observed for atazanavir sulfate (adjusted odds ratio [aOR], 1.95; 95%

184 cancer drug gefitinib or the retroviral drug atazanavir, the Por-deleted humanized PIRF mice develop

185 herapy B protease showed that the ability of atazanavir to maintain its binding affinity for variants

186 r [95% CI, 1.12-1.25]) and ritonavir-boosted atazanavir use (aIRR, 1.19/year [95% CI, 1.09-1.32]) wer

187 stimated the 'intention-to-treat' effect for atazanavir vs lopinavir regimens on each of the outcomes

188 djusted intention-to-treat hazard ratios for atazanavir vs lopinavir regimens were 0.70 (95% confiden

189 Ritonavir-boosted atazanavir was noninferior to ritonavir-boosted lopinavi

190 However, atazanavir, which does not inhibit glucose transport, ha

191 Atazanavir, which is marketed as REYATAZ, is the first h

192 which interferes with initial infection, and atazanavir, which reduces the cellular virion burst size

193 tease inhibitor regimen of ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil f

194 rase inhibitor regimen) or ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil f

195 the X-ray crystal structures of complexes of atazanavir with two HIV-1 protease variants, namely, (i)

196 aining either efavirenz or ritonavir-boosted atazanavir would alter plasma concentrations of vaginall

197 d in combination, and that ritonavir-boosted atazanavir would be noninferior to ritonavir-boosted lop